company background image
AXLA

Axcella HealthNasdaqGM:AXLA Stock Report

Market Cap

US$117.2m

7D

-5.0%

1Y

-34.8%

Updated

26 Sep, 2021

Data

Company Financials +
AXLA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

AXLA Overview

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Axcella Health
Historical stock prices
Current Share PriceUS$3.07
52 Week HighUS$2.98
52 Week LowUS$6.84
Beta1.4
1 Month Change-10.23%
3 Month Change-24.38%
1 Year Change-34.82%
3 Year Changen/a
5 Year Changen/a
Change since IPO-77.75%

Recent News & Updates

Shareholder Returns

AXLAUS BiotechsUS Market
7D-5.0%-2.3%0.1%
1Y-34.8%26.0%35.3%

Return vs Industry: AXLA underperformed the US Biotechs industry which returned 26% over the past year.

Return vs Market: AXLA underperformed the US Market which returned 35.3% over the past year.

Price Volatility

Is AXLA's price volatile compared to industry and market?
AXLA volatility
AXLA Beta1.4
Industry Beta1.03
Market Beta1

Stable Share Price: AXLA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: AXLA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200859Bill Hinshawhttps://www.axcellahealth.com

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company’s lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis.

Axcella Health Fundamentals Summary

How do Axcella Health's earnings and revenue compare to its market cap?
AXLA fundamental statistics
Market CapUS$117.21m
Earnings (TTM)-US$58.75m
Revenue (TTM)n/a

0x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AXLA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$58.75m
Earnings-US$58.75m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.54
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio52.8%

How did AXLA perform over the long term?

See historical performance and comparison

Valuation

Is Axcella Health undervalued compared to its fair value and its price relative to the market?

2.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AXLA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AXLA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AXLA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AXLA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AXLA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AXLA is good value based on its PB Ratio (2.4x) compared to the US Biotechs industry average (3.3x).


Future Growth

How is Axcella Health forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

-13.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AXLA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AXLA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AXLA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AXLA is forecast to have no revenue next year.

High Growth Revenue: AXLA is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AXLA is forecast to be unprofitable in 3 years.


Past Performance

How has Axcella Health performed over the past 5 years?

-17.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AXLA is currently unprofitable.

Growing Profit Margin: AXLA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AXLA is unprofitable, and losses have increased over the past 5 years at a rate of 17.3% per year.

Accelerating Growth: Unable to compare AXLA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AXLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: AXLA has a negative Return on Equity (-122.17%), as it is currently unprofitable.


Financial Health

How is Axcella Health's financial position?


Financial Position Analysis

Short Term Liabilities: AXLA's short term assets ($80.3M) exceed its short term liabilities ($12.0M).

Long Term Liabilities: AXLA's short term assets ($80.3M) exceed its long term liabilities ($21.4M).


Debt to Equity History and Analysis

Debt Level: AXLA's debt to equity ratio (52.8%) is considered high.

Reducing Debt: Insufficient data to determine if AXLA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AXLA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AXLA has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 16.5% each year.


Dividend

What is Axcella Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AXLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AXLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AXLA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AXLA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AXLA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Bill Hinshaw (52 yo)

3.25yrs

Tenure

US$1,934,081

Compensation

Mr. William R. Hinshaw, Jr, also known as Bill, has been President, Chief Executive Officer and Director of Axcella Health Inc. since June 2018. Prior to this role, Mr. Hinshaw held a number of leadership...


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD1.93M) is above average for companies of similar size in the US market ($USD548.10K).

Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AXLA's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: AXLA's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.


Top Shareholders

Company Information

Axcella Health Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Axcella Health Inc.
  • Ticker: AXLA
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$117.206m
  • Shares outstanding: 38.18m
  • Website: https://www.axcellahealth.com

Number of Employees


Location

  • Axcella Health Inc.
  • 840 Memorial Drive
  • 3rd Floor
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/26 22:03
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.